Control of fatty acid metabolism by leptin in L6 rat myoblasts is regulated by hyperinsulinemia

Journal of Endocrinological Investigation

Volumn 30, Issue 3, 2007, Pages 192-199

  Eguchi, M ^a   Shrivastava, S ^a   Lyakhovsky, N ^a   Kim, W ^a   Palanivel, R ^a   Sweeney, G ^a  

^a YORK UNIVERSITY   (Canada)

Author keywords

Diabetes; Fatty acid uptake; Metabolic syndrome; Obesity

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; BORON; FATTY ACID; INSULIN; LEPTIN; LONG CHAIN FATTY ACID; MESSENGER RNA; PALMITIC ACID; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRITIUM;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME PHOSPHORYLATION; FATTY ACID METABOLISM; FATTY ACID TRANSPORT; HYPERINSULINEMIA; INCUBATION TIME; MUSCLE CELL; MYOBLAST; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATION; PROTEIN CONTENT; QUANTITATIVE ANALYSIS; RAT; SKELETAL MUSCLE; TIME;

EID: 34250647881     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347424     Document Type: Article

References (39)

1. Maffei M, Halaas J, Ravussin E, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1995, 1: 1155-61.
2. Ahima RS, Flier JS. Leptin. Annu Rev Physiol 2000, 62: 413-37.
3. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998, 395: 763-70.
4. Bjorbaek C, Elmquist JK, Frantz JD, Shoelson SE, Flier JS. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell 1998, 1: 619-25.
5. Bjorbaek C, El-Haschimi K, Frantz JD, Flier JS. The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem 1999,274:30059-65.
6. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000;106: 473-81.
7. Schernthaner GH, Schernthaner G. Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention. Scand J Clin Lab Invest Suppl 2005, 240: 30-40.
8. Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 2000, 275: 15985-91.
9. Sadowski CL, Choi TS, Le M, Wheeler TT, Wang LH, Sadowski HB. Insulin induction of SOCS-2 and SOCS-3 mRNA expression in C2C12 skeletal muscle cells is mediated by Stat5. J Biol Chem 2001, 276: 20703-10.
10. Chen JC, Goldhamer DJ. Skeletal muscle stem cells. Reprod Biol Endocrinol 2003,1: 101.
11. Roden M. Muscle triglycerides and mitochondrial function: possible mechanisms for the development of type 2 diabetes. Int J Obes (Lond) 2005, 29 (Suppl 2): S111-5.
12. Unger RH, Orci L. Lipotoxic diseases of nonadipose tissues in obesity. Int J Obes Relat Metab Disord 2000, 24 Suppl 4: S28-32.
13. Tajmir P, Kwan JJ, Kessas M, Mozammel S, Sweeney G. Acute and chronic leptin treatment mediate contrasting effects on signaling, glucose uptake, and GLUT4 translocation in L6-GLUT4myc myotubes. J Cell Physiol 2003, 197: 122-30.
14. Fang X, Palanivel R, Zhou X, Liu Y, Xu A, Wang Y, Sweeney G. Hyperglycemia- and hyperinsulinemia-induced alteration of adiponectin receptor expression and adiponectin effects in L6 myoblasts. J Mol Endocrinol 2005, 35: 465-76.
15. Palanivel R, Sweeney G. Regulation of fatty acid uptake and metabolism in L6 skeletal muscle cells by resistin. FEBS Lett 2005, 579: 5049-54.
16. Madani S, De Girolamo S, Munoz DM, Li RK, Sweeney G. Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovasc Res 2006, 69: 716-25.
17. Munday MR. Regulation of mammalian acetyl-CoA carboxylase. Biochem Soc Trans 2002, 30: 1059-64.
18. Brownsey RW, Boone AN, Elliott JE, Kulpa JE, Lee WM. Regulation of acetyl-CoA carboxylase. Biochem Soc Trans 2006, 34: 223-7.
19. Arch JR. Central regulation of energy balance: inputs, outputs and leptin resistance. Proc Nutr Soc 2005, 64: 39-46.
20. Sahu A. Leptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin resistance. Front Neuroendocrinol 2003, 24: 225-53.
21. Ceddia RB, Koistinen HA, Zierath JR, Sweeney G. Analysis of paradoxical observations on the association between leptin and insulin resistance. Faseb J 2002, 16: 1163-76.
22. Tataranni PA, Ravussin E. Variability in metabolic rate: biological sites of regulation. Int J Obes Relat Metab Disord 1995, 19 (Suppl 4): S102-6.
23. Unger RH. Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine. Biochimie 2005, 87: 57-64.
24. Unger RH. Lipotoxic diseases. Annu Rev Med 2002; 53: 319-36. 25.
25. van der Vleuten GM, Kluijtmans LA, Hijmans A, Blom HJ, Stalenhoef AF, de Graaf J. The Gln223Arg polymorphism in the leptin receptor is associated with familial combined hyperlipidemia. Int J Obes (Lond) 2006, 30: 892-8.
26. Ukkola O, Bouchard C. Role of candidate genes in the responses to long term overfeeding: review of findings. Obes Rev 2004, 5: 3-12.
27. Ueki K, Kadowaki T, Kahn CR. Role of suppressors of cytokine signaling SOCS-1 and SOCS-3 in hepatic steatosis and the metabolic syndrome. Hepatol Res 2005, 33: 185-92.
28. Lindberg K, Ronn SG, Tornehave D, et al. Regulation of pancreatic beta-cell mass and proliferation by SOCS-3. J Mol Endocrinol 2005, 35: 231-43.
29. Carey AL, Petersen EW, Bruce CR, et al. Discordant gene expression in skeletal muscle and adipose tissue of patients with type 2 diabetes: effect of interleukin-6 infusion. Diabetologia 2006, 49: 1000-7.
30. Emanuelli B, Glondu M, Filloux C, Peraldi P, Van Obberghen E. The potential role of SOCS-3 in the interleukin-1beta-induced desensitization of insulin signaling in pancreatic beta-cells. Diabetes 2004, 53 (Suppl 3): S97-S103.
31. Rieusset J, Bouzakri K, Chevillotte E, et al. Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 2004, 53: 2232-41.
32. Muoio DM, Dohm GL, Fiedorek FT, Jr., Tapscott EB, Coleman RA. Leptin directly alters lipid partitioning in skeletal muscle. Diabetes 1997, 46: 1360-3.
33. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002, 415: 339-43.
34. Steinberg GR, Parolin ML, Heigenhauser GJ, Dyck DJ. Leptin increases FA oxidation in lean but not obese human skeletal muscle: evidence of peripheral leptin resistance. Am J Physiol Endocrinol Metab 2002, 283: E187-92.
35. Steinberg GR, Dyck DJ. Development of leptin resistance in rat soleus muscle in response to high-fat diets. Am J Physiol Endocrinol Metab 2000, 279: E1374-82.
36. Ramsay TG. Porcine leptin inhibits protein breakdown and stimulates fatty acid oxidation in C2C12 myotubes. J Anim Sci 2003, 81: 3046-51.
37. Hamann A, Matthaei S. Regulation of energy balance by leptin. Exp Clin Endocrinol Diabetes 1996, 104: 293-300.
38. Oral EA, Simha V, Ruiz E, et al. Leptin replacement therapy for lipodystrophy. N Engl J Med 2002, 346: 570-8.
39. Reitman ML, Mason MM, Moitra J, et al. Transgenic mice lacking white fat: models for understanding human lipoatrophic diabetes. Ann N Y Acad Sci 1999, 892; 289-96.